National awards program highlights the
importance of community partnerships in redefining cancer care and
providing equitable access to quality treatments and
resources
AstraZeneca, in partnership with Scientific American Custom
Media, today announced the winners of the fourth annual Cancer
Community Awards (C2 Awards). A part of the AstraZeneca YOUR Cancer
program, the C2 Awards celebrate and recognize inspiring work that
exemplifies the full promise of community partnerships in advancing
equitable access to quality cancer care.
The five awardees were revealed last night during a virtual
ceremony, honoring the contributions they have made for people with
cancer and their loved ones.
“As we continue pushing the boundaries of science to develop
novel cancer treatments, I am proud to support those that are
working to improve greater access to quality cancer care for
communities nationwide,” said Chatrick Paul, Head of US Oncology,
AstraZeneca. “The work of the organizations here tonight is an
inspiration to others and demonstrates what can be accomplished
when we come together as one oncology community working
collectively to eliminate cancer as a cause of death.”
“For the fourth year in a row, the inspiring work and proven
approaches of those redefining cancer care strengthen and encourage
the oncology community, far and wide,” noted Jeremy Abbate, Vice
President & Publisher of Scientific American. “The C2 Awards
provide a platform for elevating unsung heroes who have created
important partnerships in their own communities, bringing together
fellow innovators and changemakers to offer new hope for those
affected by this devastating disease.”
The awardees, selected by a third-party judging panel consisting
of leaders in the cancer community, will receive a $50,000 donation
for a non-profit organization serving the oncology community.
The 2022 awardees and finalists across all five award categories
are:
The 2022 Cancer Community Awards
Recipients
The C2 Catalyst for Care Award recognizes those who work
to improve the care experience of those with cancer.
- This year’s winner is Sparrow’s Nest of the Hudson Valley,
represented by founder and executive director Krista Jones.
Sparrow’s Nest provides weekly deliveries of homemade meals to
families facing cancer in five counties of the Hudson Valley area
of New York State. Sparrow’s Nest began in Krista’s home kitchen as
a personal commitment to helping a friend navigate her stage 4
cancer diagnosis and evolved into a charity that now feeds nearly
300 people each week
- Finalists included Cancer Family Care, represented by Jill
Settlemyre, MPA, a nonprofit organization that helps children,
adults, and families cope with the effects of a cancer diagnosis
for more than 50 years; and Huntsman at Home, represented by
Kathi Mooney, RN, PhD, an at-home cancer program in the United
States that includes acute, hospital-level care for treatment side
effects and disease progression
The C2 Catalyst for Change Award honors those ensuring
cancer care advancements reach the community level and underserved
populations.
- This year’s winner is Charles R. Rogers, PhD, MPH, an
Endowed Associate Professor at the Institute for Health &
Equity at the Medical College of Wisconsin. For more than 10
years, his work has centered on eliminating men's health
disparities, with a focus on removing barriers to achieving
colorectal cancer equity among African American men and other
underserved populations
- Finalists included Marianne T. Ritchie, MD, Clinical
Associate Professor of Medicine at Sidney Kimmel Medical College at
Thomas Jefferson University, who has been a pioneer in
gastroenterology for over 35 years and spearheaded the PINK PLUS®
program, an innovative, bundled cancer-screening program; and
The Thoracic Oncology Department at Baptist Cancer Center
which works to eliminate lung cancer stigma and mortality for all
patients affected by this disease
The C2 Catalyst for Equity Award recognizes those who
have worked to break down barriers to care, ensuring historically
underserved and underrepresented populations have access to
life-saving cancer screenings and treatments.
- This year’s winner is Center for H.O.P.E., represented by
David Wetter, PhD. The Center for Health Outcomes and
Population Equity (H.O.P.E.) serves as an infrastructure and bridge
between scientists and community organizations to create long-term
solutions to prevent cancer and improve health among populations
that have been historically marginalized
- Finalists included Nina Bickell, MD, MPH, of the Institute
for Health Equity Research at Icahn School of Medicine, for her
work in identifying and addressing inequities in cancer and cancer
care delivery by partnering with communities to change systems and
improve care processes and outcomes; and Kathy Levy of GO2
Foundation for Lung Cancer for her widespread use of community
health advisors to educate and navigate high-risk individuals to
lung cancer screening and increased access to quality screening in
rural counties in Alabama
The C2 Catalyst for Precision Medicine Award honors those
who have expanded beyond the boundaries of personalized treatment
for cancer patients.
- This year’s winner is Marc Matrana, MD, of Ochsner
Health, whose legislative advocacy work and leadership at the
Cancer Advocacy Group of Louisiana (where he is Co-Chair of the
Scientific Advisory Board) has led to the passage of many laws
ensure Louisiana cancer patients have access to cutting-edge
molecular diagnostics and therapies
- Finalists included Alana Welm, PhD, of the Huntsman Cancer
Center, who is working to extend precision medicine to testing
the activity of drugs on models made from individual tumors, in
addition to the latest approaches in genomics-based precision
oncology; and Mark Burkard, MD, PhD, of the University of
Wisconsin-Madison, who works to make precision oncology
accessible to every patient in the community across Wisconsin by
identifying the best treatment or clinical trial option
The C2 President’s Award, selected by AstraZeneca,
recognizes those who work to make a meaningful and inspirational
impact on the lives of people with cancer and their loved ones.
- This year’s President’s Award winner is Douglas Fair, MD, of
the University of Utah, who works to provide
fertility-preservation consultations for reproductive-age cancer
patients who want to have children, creating impacts at the local,
regional, and national levels. He has consulted with hundreds of
patients and educated hundreds of providers in the Intermountain
West working to help people affected by cancer alleviate that
distress
Nominations were evaluated by an esteemed panel of
multidisciplinary community leaders, including Andrea
Ferris, President & CEO of the LUNGevity Foundation;
Colin Pritchard, MD, PhD, 2021 C2 Catalyst for Precision
Medicine Winner and Director of Clinical Diagnostics at the Brotman
Baty Institute for Precision Medicine of UW; Ellen Miller
Sonet, MBA, JD, Senior Vice President, Chief Strategy and
Policy Officer of CancerCare; Leigh M. Boehmer, PharmD,
BCOP, Chief Medical Officer of the Association of Community Cancer
Centers; Margaret Stauffer, 2021 C2 President’s Award Winner
and Chief Mission Officer of the Cancer Support Community San
Francisco Bay Area; Paris Thomas, MS, MCHES, 2021 C2
Catalyst for Equity Winner Representative and Director of Program
Operations at Equal Hope; Pamela Tarapchak, Managing Editor
at Oncology Times; Susan Weldon, 2021 C2 Catalyst for Care
Winner Representative and CEO & Founder of Unite for HER; and
Tomma Hargraves, 2021 C2 Catalyst for Change Winner and Lung
Cancer Advocate & Volunteer at the Lung Cancer Initiative of
North Carolina. More details on finalists and winners can be found
at https://yourcancer.org/the-c2-awards/main-2022/.
About YOUR Cancer
The C2 Awards are part of the YOUR Cancer Program, a broader
initiative launched by AstraZeneca to spotlight those at the
forefront of cancer research and patient support who are
contributing toward eliminating cancer as a cause of death.
YOUR Cancer aims to convene, engage,
and highlight the full breadth of the oncology community, utilizing
four pillars: a digital partnership hub profiling community
resources and perspectives, an awards program recognizing the
unsung heroes of oncology, state-level roundtables with local
policymakers and advocates, and media and speaking engagements
profiling community oncology leaders.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the
ambition to provide cures for cancer in every form, following the
science to understand cancer and all its complexities to discover,
develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyze changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development, and commercialization
of prescription medicines in Oncology, Rare Diseases, and
BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge,
UK, AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
www.astrazeneca-us.com and follow the Company on Twitter
@AstraZenecaUS.
US-68032 Last Updated 9/22
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221020005093/en/
Media Inquiries Brendan McEvoy +1 302 885 2677 Chelsea
Ford +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024